Biotricity Inc
NASDAQ:BTCY
Biotricity Inc
Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. The company is headquartered in Redwood City, California and currently employs 44 full-time employees. The company went IPO on 2015-10-26. The firm developed its Bioflux MCT technology, comprised of a monitoring device and an ECG reporting software component. The Bioflux device is comprised of a wet electrode and worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patient’s electrocardiogram (ECG) data for monitoring and diagnostic purposes. Both the device and software are in accordance with mobile cardiac telemetry (MCT) billing code standards, compliant with arrhythmia devices and alarms, and require 510000 clearance, which has been obtained. The Bioflux device has been developed, among other things, with global system for mobile communications (GSM) mobile chip for global cellular network compatibility; touch-screen liquid crystal display (LCD) viewer; and extended battery pack for an additional approximately 48 hours of battery life.
Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. The company is headquartered in Redwood City, California and currently employs 44 full-time employees. The company went IPO on 2015-10-26. The firm developed its Bioflux MCT technology, comprised of a monitoring device and an ECG reporting software component. The Bioflux device is comprised of a wet electrode and worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patient’s electrocardiogram (ECG) data for monitoring and diagnostic purposes. Both the device and software are in accordance with mobile cardiac telemetry (MCT) billing code standards, compliant with arrhythmia devices and alarms, and require 510000 clearance, which has been obtained. The Bioflux device has been developed, among other things, with global system for mobile communications (GSM) mobile chip for global cellular network compatibility; touch-screen liquid crystal display (LCD) viewer; and extended battery pack for an additional approximately 48 hours of battery life.
Revenue Growth: Biotricity reported third quarter revenue of $4 million, up 10.2% year-over-year, driven by strong adoption of its cardiac monitoring solutions.
Profitability Progress: The company achieved its third consecutive quarter of positive EBITDA and positive net operating income, signaling a sustained move toward profitability.
Gross Margin Expansion: Gross margin improved to 81.5%, up 516 basis points from the prior year, aided by recurring technology fees and operational efficiencies.
Cost Management: Operating expenses fell by 4.2% year-over-year, with SG&A down 8.2% and ongoing investment in R&D.
AI and Product Milestones: Biotricity expanded its AI-driven cardiac platform, launched new pilots for Biocore Pro, and is pursuing further FDA and international regulatory clearances.
Outlook: Management expects continued revenue growth and anticipates turning net income positive during 2026.
